Abstract: An OLED display device includes a first substrate; organic light-emitting diodes each including a first electrode, an organic light-emitting layer and a second electrode on the first substrate; a passivation layer on the organic light-emitting diodes; a second substrate spaced apart from the first substrate; a color filter layer on an inner surface of the second substrate; and a color changing layer contacting the passivation layer and the color filter layer.

Abstract: An OLED display device includes a first substrate; organic light-emitting diodes each including a first electrode, an organic light-emitting layer and a second electrode on the first substrate; a passivation layer on the organic light-emitting diodes; a second substrate spaced apart from the first substrate; a color filter layer on an inner surface of the second substrate; and a color changing layer contacting the passivation layer and the color filter layer.

Abstract: Disclosed herein is a composite of a nanoscale particle size. The composite is able to specifically deliver therapeutic agents such as therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects of the therapeutic agents. The composite may be comprised of an apolipoprotein A-1 and a liposome-forming material. A composition containing the composite and a pharmaceutically acceptable carrier is disclosed.

Abstract: A linear double-stranded RNA molecule, which comprises two or more consecutively or convergently linked short interfering RNAs (siRNAs) each reducing the expression of one of different target genes, and a recombinant expression vector comprising double-stranded DNA sequence expressing the linear double-stranded RNA molecule are provided. The linear double-stranded RNA molecule or the recombinant expression vector is useful for a method of reducing expression of target genes in a cell, the method comprising introducing the linear double-stranded RNA molecule or the recombinant expression vector into the cell, whereby the encoded siRNAs target different genes and reduce expression of the target genes. It was also proved that effective gene silencing activity can be induced when each siRNA unit within the linear double-stranded RNA molecule has 18 to 24 nucleotides and, additionally, the gene silencing activity is not affected by inverted orientation of an siRNA.

Abstract: The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents.

Abstract: A method for enhancing the serum stability and lowering the immunostimulatory property of a small interfering ribonucleic acid (siRNA) which mediates RNA interference (RNAi) against a viral gene expression of hepatitis B virus (HBV) or hepatitis C virus (HCV) is provided.

Abstract: The present invention relates to RNA interference mediated inhibition of Hepatitis B virus (HBV) by short interfering RNA (siRNA) molecules. Specially, siRNAs of the present invention which are double-stranded RNAs concern directing the sequence-specific degradation of viral RNA in mammalian cells. Disclosed is a DNA vector encoding the RNA molecules and synthesized siRNA molecules as well as method of therapeutic treatment for inhibition of HBV gene expression and viral replication by the administration of RNA molecules of the present invention.

Abstract: The present invention relates to a therapeutic reagent for hepatitis C comprising HCV specific short interfering RNA (siRNA) as an effective ingredient. The siRNA of the invention is a double-stranded RNA specific for the nucleotide sequence of HCV which induces viral RNA degradation in mammalian cells and thereby inhibits HCV protein expression and replication. The method of the invention, which includes the step of administrating the synthetic siRNA or a DNA vector encoding the RNA, is thus effective for the treatment of HCV carrier by inhibiting HCV gene expression and replication.

Abstract: The invention belongs to the field of biologically active peptides specifically stimulating antiviral, antimicrobial and antitumor activity of the human and animal immune system.

Abstract: The inventive composite having a nanoscale particle size can specifically deliver therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects without inducing any enzymatic abnormalities or pathological damage to the normal liver function, when administered together with the therapeutic agents.

Abstract: The present invention relates to liposome complex comprising a novel disintegrin, saxatilin, gene derived from Agkistrodon saxatilis and methods for curing and preventing tumors by transferring the complexes to a living body.

Abstract: The invention belongs to the field of biologically active peptides specifically stimulating antiviral, antimicrobial and antitumor activity of the human and animal immune system.

Abstract: The invention belongs to the field of biologically active peptides specifically stimulating antiviral, antimicrobial and antitumor activity of the human and animal immune system.

Abstract: The invention belongs to the field of biologically active peptides specifically stimulating antiviral, antimicrobial and antitumor activity of the human and animal immune system.

Abstract: The present invention is concerned with immunomodulatory and antimicrobial peptide materials obtainable from the body fluid of invertebrates, especially insects.

Abstract: The present invention is concerned with immunomodulatory and antimicrobial peptide materials obtainable from the body fluid of invertebrates, especially insects.

Abstract: A cold plasma coagulator clots blood bleeding from tissue during surgical operation in an effective manner, by applying unipolar cold plasma to the blood. The cold plasma coagulator has a high frequency power supply, gas dynamic block and plasmotron. The power supply has a rectifier, capacitor storage and voltage inverter. The said plasmotron is assembled in a hermetically sealed case and in which resonance inductor and dielectric tube are located coaxially. One end of the dielectric tube is connected to the gas dynamic block, another end is positioned to eject plasma through output nozzle. A needle corona electrode is located along the axis of the dielectric electrode. The coils of the resonance inductor has a low voltage and high voltage section, the low voltage section of resonance coils being connected to output of the voltage inverter. One pin of the high voltage section is isolated and another one is connected to the needle corona electrode.

Abstract: The present invention relates to a plasma generator to apply cold plasma in the fields of medicine, biology, ecological recovery, activation, purification, special processing of gases, liquids and solid substances as well as other areas of technology and science. A plasma generator of the invention comprises: a power source; an electronic oscillator constructed on an amplifying (control) element which is connected to a low voltage input section; a resonance transformer having a low voltage input section and a high voltage output section; and, one pin of the high voltage output section of the resonance transformer which is connected to a discharge electrode. The present invention provides a universal plasma generator with decreased mass and dimensions which provides unipolar plasma for plasma therapy and activation of substantial media by virtue of the field.